Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;27(5):341-349.
doi: 10.1111/resp.14234. Epub 2022 Feb 27.

Direct and indirect costs of systemic sclerosis and associated interstitial lung disease: A nationwide population-based cohort study

Malene Knarborg  1   2 , Anders Løkke  1   2 , Ole Hilberg  1   2 , Rikke Ibsen  3 , Melina Gade Sikjaer  1   2
Affiliations

Direct and indirect costs of systemic sclerosis and associated interstitial lung disease: A nationwide population-based cohort study

Malene Knarborg et al. Respirology. 2022 May.

Abstract

Background and objective: The study aimed to evaluate the direct and indirect costs of systemic sclerosis (SSc) in cases with and without interstitial lung disease (ILD).

Methods: Cases diagnosed with SSc (2002-2015) were identified in the Danish National Patient Registry. Cases were matched 1:4 with non-SSc controls from the general population. Data on costs were obtained from national databases. Excess cost was estimated as the annual cost per case subtracting the costs of the control.

Results: We identified 1869 cases and 7463 controls. Total excess cost (direct healthcare, elderly care and indirect costs) in the SSc-ILD cohort was €29,725, and €17,905 in the non-ILD SSc cohort. In- and out-patient contacts and forgone earnings were the key drivers of costs in both cohorts. Healthcare costs were higher before and after the diagnosis compared with the controls. Men incurred higher excess healthcare costs than women. Hospitalization and outpatient services were the key drivers of the gender-associated differences. Income from employment decreased more rapidly after diagnosis in the SSc-ILD cohort than in the non-ILD SSc cohort. Public transfer income increased after diagnosis, with the most pronounced difference in the SSc-ILD cohort. Disability pension was the key driver of public transfer income.

Conclusion: SSc is associated with a significant individual and societal burden that is evident several years before and after the diagnosis. Total excess costs are higher in SSc-ILD than in the non-ILD SSc underlining the severity of pulmonary involvement. Initiatives to maintain work ability and to reduce hospital admissions may reduce the economic burden of SSc.

Keywords: cost of illness; direct healthcare cost; healthcare cost; indirect costs; systemic sclerosis-associated interstitial lung disease.

PubMed Disclaimer

Conflict of interest statement

Ole Hilberg has received an unrestricted grant from Boehringer Ingelheim A/S for the current work. Outside the current work, Malene Knarborg has received a fee from AstraZenica A/S. Melina Gade Sikjær, Anders Løkke and Rikke Ibsen declare no competing interests.

Figures

FIGURE 1
FIGURE 1
Healthcare costs, income from employment and public transfer income in euros (€) of all systemic sclerosis cases and matched controls distributed by age and sex
FIGURE 2
FIGURE 2
(A) Total healthcare costs, (B) income from employment and (C) public transfer income in euros (€) before and after the diagnosis of systemic sclerosis (SSc) in the SSc‐interstitial lung disease (SSc‐ILD) and non‐ILD SSc cohorts compared with the matched controls. Year 0 = year of SSc diagnosis
See this image and copyright information in PMC

Comment in

References

    1. Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685–99. - PubMed
    1. Bergamasco A, Hartmann N, Wallace L, Verpillat P. Epidemiology of systemic sclerosis and systemic sclerosis‐associated interstitial lung disease. Clin Epidemiol. 2019;11:257–73. - PMC - PubMed
    1. Hudson M, Steele R, Lu Y, Thombs BD, Baron M. Work disability in systemic sclerosis. J Rheumatol. 2009;36(11):2481–6. - PubMed
    1. Tyndall AJ, Bannert B, Vonk M, Airò P, Cozzi F, Carreira PE, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69(10):1809–15. - PubMed
    1. Mayes MD, Lacey JV Jr, Beebe‐Dimmer J, Gillespie BW, Cooper B, Laing TJ, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003;48(8):2246–55. - PubMed

Publication types